3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
7
Breast Neoplasms
6
Colorectal Neoplasms
4
Ovarian Neoplasms
3
Neuroblastoma
3
Neoplasm Metastasis
3
Uveal Melanoma
2
Unspecified Adult Solid Tumor, Protocol Specific
2
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Lung Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms, Male
2
Adenocarcinoma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms, Plasma Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Interventions
pembrolizumab
17
Cisplatin
11
Carboplatin
9
Cyclophosphamide
8
fludarabine
6
Paclitaxel
6
Nivolumab
6
Bevacizumab
6
aldesleukin
5
Radiotherapy
5
toripalimab
4
tisotumab vedotin
4
fludarabine phosphate
4
Topotecan
4
Interleukin-2
4
Docetaxel
4
Brachytherapy
4
spartalizumab
3
Ipilimumab
3
Fulvestrant
3
ferumoxtran-10
2
enzalutamide
2
durvalumab
2
cemiplimab
2
bemarituzumab
2
balstilimab
2
Trastuzumab
2
Radiation
2
Magnetic Resonance Spectroscopy
2
Injections
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Uterine Cervical Neoplasms
×
sargramostim
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled